Protocol PDX-012: A Randomized, Phase 2b, Multi-Center Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-Based Treatment.

Trial Profile

Protocol PDX-012: A Randomized, Phase 2b, Multi-Center Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-Based Treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2015

At a glance

  • Drugs Pralatrexate (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Apr 2012 Results published in the Journal of Thoracic Oncology.
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database record, EudraCT2007-004673-26).
    • 01 Jul 2011 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top